Abstract
Objective: Soluble receptor for advanced glycation end products (sRAGE) levels have been found to be decreased in chronic inflammatory diseases including atherosclerosis, hypertension and renal failure. This study evaluated the relationship between sRAGE concentrations and urinary albumin excretion in patients with essential hypertension. Methods: A total of 200 consecutive patients with essential hypertension were enrolled and were divided into 3 groups. Results: Plasma sRAGE levels were significantly lower in hypertensive patients with micro- or macroalbuminuria compared with those in hypertensive patients with normoalbuminuria, and the values in the macroalbuminuria group were even lower than in the microalbuminuria group (128.6±24.2, 244.6±37.6313.6±30.7 pg/ml respectively). In addition, plasma sRAGE level was an independent determinant of log urinary albumin excretion in patients with essential hypertension (β=0.267, P<0.05). Conclusions: sRAGE may play a role in the pathogenic processes that link albuminuria, chronic inflammation and oxidative stress in hypertensive patients.
Keywords: Albuminuria, hypertension, receptor for advanced glycation end products.
Current Vascular Pharmacology
Title:Association of Soluble Receptor for Advanced Glycation End Products Levels with Hypertensive Albuminuria
Volume: 13 Issue: 2
Author(s): Huan Zheng, Lingyan Yuan, Nanzi Xie, Huifeng Xu, Xiaoyun Xie and Ming Luo
Affiliation:
Keywords: Albuminuria, hypertension, receptor for advanced glycation end products.
Abstract: Objective: Soluble receptor for advanced glycation end products (sRAGE) levels have been found to be decreased in chronic inflammatory diseases including atherosclerosis, hypertension and renal failure. This study evaluated the relationship between sRAGE concentrations and urinary albumin excretion in patients with essential hypertension. Methods: A total of 200 consecutive patients with essential hypertension were enrolled and were divided into 3 groups. Results: Plasma sRAGE levels were significantly lower in hypertensive patients with micro- or macroalbuminuria compared with those in hypertensive patients with normoalbuminuria, and the values in the macroalbuminuria group were even lower than in the microalbuminuria group (128.6±24.2, 244.6±37.6313.6±30.7 pg/ml respectively). In addition, plasma sRAGE level was an independent determinant of log urinary albumin excretion in patients with essential hypertension (β=0.267, P<0.05). Conclusions: sRAGE may play a role in the pathogenic processes that link albuminuria, chronic inflammation and oxidative stress in hypertensive patients.
Export Options
About this article
Cite this article as:
Zheng Huan, Yuan Lingyan, Xie Nanzi, Xu Huifeng, Xie Xiaoyun and Luo Ming, Association of Soluble Receptor for Advanced Glycation End Products Levels with Hypertensive Albuminuria, Current Vascular Pharmacology 2015; 13 (2) . https://dx.doi.org/10.2174/1570161111666131209143650
DOI https://dx.doi.org/10.2174/1570161111666131209143650 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
Current Pharmaceutical Design Modulation of Energy Intake and Expenditure Due to Habitual Physical Exercise
Current Pharmaceutical Design Uremia, Atherothrombosis and Malnutrition: The Role of L-arginine- Nitric Oxide Pathway
Cardiovascular & Hematological Disorders-Drug Targets Matrix Metalloproteinases as Drug Targets in Preeclampsia
Current Drug Targets Phylogenetic Aspects of Nucleobindin-2/Nesfatin-1
Current Pharmaceutical Design Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities
CNS & Neurological Disorders - Drug Targets Vascular Risk Factors, Vascular Diseases, and Imaging Findings in a Hospital-based Cohort of Mild Cognitive Impairment Types
Current Alzheimer Research Greener Liquid Chromatography for Simultaneous Determination of Rosiglitazone and Glimepiride in Rat Sera and its Application to a Pharmacokinetic Study
Current Analytical Chemistry Beneficial Effects of Corn Silk on Metabolic Syndrome
Current Pharmaceutical Design The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design The Effect of Polyphenol Consumption on Blood Pressure
Mini-Reviews in Medicinal Chemistry Effect of Simvastatin use on Autonomic Function in Patients with End Stage Renal Disease
Cardiovascular & Hematological Disorders-Drug Targets Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update
Current Cardiology Reviews Mast Cell Stabilizers in the Treatment of Allergic Rhinitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Possible Non-Classic Intracellular and Molecular Mechanisms of LDL Cholesterol Action Contributing to the Development and Progression of Atherosclerosis
Current Vascular Pharmacology Synthetic Cannabinoids as Drugs of Abuse
Current Drug Abuse Reviews The Role of Diabetes in Molecular Pathogenesis of Cancer
Current Signal Transduction Therapy The Effect of First-in-Class Small Molecule RhoA Inhibitor, HL07, on the Phenylephrine-induced Artery Contraction
Current Pharmaceutical Design Why and How We Should Treat Elderly Patients with Hypertension?
Current Vascular Pharmacology Dopamine β-Monooxygenase: Mechanism, Substrates and Inhibitors
Current Enzyme Inhibition